MetLife Investment Management LLC grew its holdings in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 8.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 99,019 shares of the company's stock after purchasing an additional 7,618 shares during the quarter. MetLife Investment Management LLC owned 0.11% of HealthEquity worth $9,501,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Pier Capital LLC acquired a new position in shares of HealthEquity in the fourth quarter worth $8,024,000. HighTower Advisors LLC boosted its holdings in HealthEquity by 4.8% in the fourth quarter. HighTower Advisors LLC now owns 95,075 shares of the company's stock valued at $9,122,000 after purchasing an additional 4,370 shares during the period. Geneva Capital Management LLC grew its stake in HealthEquity by 24.6% during the 4th quarter. Geneva Capital Management LLC now owns 1,048,903 shares of the company's stock worth $100,642,000 after purchasing an additional 206,894 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in HealthEquity by 2.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,086,811 shares of the company's stock worth $104,280,000 after purchasing an additional 25,004 shares during the period. Finally, Wells Fargo & Company MN raised its position in HealthEquity by 4.7% in the 4th quarter. Wells Fargo & Company MN now owns 124,940 shares of the company's stock valued at $11,988,000 after purchasing an additional 5,594 shares in the last quarter. Institutional investors and hedge funds own 99.55% of the company's stock.
Insider Transactions at HealthEquity
In other news, EVP Michael Henry Fiore sold 8,881 shares of the stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $78.26, for a total transaction of $695,027.06. Following the completion of the sale, the executive vice president now owns 56,655 shares in the company, valued at approximately $4,433,820.30. This represents a 13.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert W. Selander sold 5,750 shares of the business's stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $77.65, for a total value of $446,487.50. Following the completion of the transaction, the director now owns 84,969 shares in the company, valued at $6,597,842.85. This trade represents a 6.34 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 20,381 shares of company stock worth $1,781,432. Insiders own 2.20% of the company's stock.
Wall Street Analysts Forecast Growth
HQY has been the subject of a number of analyst reports. Raymond James raised HealthEquity from an "outperform" rating to a "strong-buy" rating and lowered their price objective for the stock from $120.00 to $115.00 in a research report on Tuesday, March 25th. Wells Fargo & Company increased their price objective on shares of HealthEquity from $110.00 to $125.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. KeyCorp reduced their price objective on shares of HealthEquity from $110.00 to $100.00 and set an "overweight" rating on the stock in a report on Wednesday, April 16th. Barrington Research reiterated an "outperform" rating and set a $112.00 target price on shares of HealthEquity in a research note on Friday, April 11th. Finally, The Goldman Sachs Group cut their price target on HealthEquity from $107.00 to $94.00 and set a "neutral" rating on the stock in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $111.75.
Read Our Latest Report on HQY
HealthEquity Stock Performance
Shares of HealthEquity stock traded up $0.04 on Friday, hitting $85.87. The stock had a trading volume of 559,483 shares, compared to its average volume of 771,464. The stock has a market cap of $7.43 billion, a price-to-earnings ratio of 78.78, a P/E/G ratio of 1.60 and a beta of 0.49. HealthEquity, Inc. has a 52-week low of $65.01 and a 52-week high of $115.59. The company's 50 day moving average price is $91.87 and its 200 day moving average price is $96.42. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.51.
About HealthEquity
(
Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Further Reading
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
